What is Prime Medicine's D&A?

Prime Medicine (PRME) reported D&A of $1.86M in Q1 2026.

How has Prime Medicine's D&A changed year-over-year?

Prime Medicine's D&A increased by 9.2% year-over-year, from $1.7M to $1.86M.

What is the long-term trend for Prime Medicine's D&A?

Over 3 years (2022 to 2025), Prime Medicine's D&A has grown at a 48.8% compound annual growth rate (CAGR), from $2.22M to $7.32M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Prime Medicine PRME D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Intellia TherapeuticsNTLA

$2.2M-11.8%

CRISPR TherapeuticsCRSP

$4.32M-8.8%

Beam TherapeuticsBEAM

$5.61M+1.4%

RegenxbioRGNX

$3.86M-2.5%

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's D&A?: Prime Medicine (PRME) reported D&A of $1.86M in Q1 2026.
How has Prime Medicine's D&A changed year-over-year?: Prime Medicine's D&A increased by 9.2% year-over-year, from $1.7M to $1.86M.
What is the long-term trend for Prime Medicine's D&A?: Over 3 years (2022 to 2025), Prime Medicine's D&A has grown at a 48.8% compound annual growth rate (CAGR), from $2.22M to $7.32M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.